– 2.4 g/dL mean increase in hemoglobin at 24 weeks
– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis
– 
Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 –